Groupe Bruxelles Lambert/€GBLB
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Groupe Bruxelles Lambert
Groupe Bruxelles Lambert (GBL) is an investment holding company founded in 1902 and headquartered in Brussels, Belgium. The company operates primarily in the financial services sector, focusing on long-term investments in industrial, services, and financial companies across Europe. GBL aims to create long-term value by actively supporting the strategic and operational development of its investments, utilizing a diverse portfolio to ensure stable and sustainable returns.
- Ticker
- €GBLB
- Sector
- Finance
- Primary listing
- BSE
- Employees
- -
- Headquarters
- Brussels, Belgium
- Website
- www.gbl.be
GBLB Metrics
BasicAdvanced
€9.3B
-
-€4.96
0.67
€3.59
4.62%
Price and volume
Market cap
€9.3B
Beta
0.67
52-week high
€85.55
52-week low
€71.50
Average daily volume
104K
Dividend rate
€3.59
Financial strength
Current ratio
2.453
Quick ratio
1.86
Long term debt to equity
0.579
Total debt to equity
0.632
Interest coverage (TTM)
1.26%
Profitability
EBITDA (TTM)
917.9
Gross margin (TTM)
70.52%
Net profit margin (TTM)
-9.31%
Operating margin (TTM)
6.68%
Effective tax rate (TTM)
0.31%
Management effectiveness
Return on assets (TTM)
1.12%
Return on equity (TTM)
-3.83%
Valuation
Price to revenue (TTM)
1.459
Price to book
0.87
Price to tangible book (TTM)
2.3
Price to free cash flow (TTM)
-60.826
Free cash flow yield (TTM)
-1.64%
Free cash flow per share (TTM)
-1.277
Dividend yield (TTM)
4.62%
Forward dividend yield
4.62%
Growth
Revenue change (TTM)
9.29%
Earnings per share change (TTM)
530.23%
3-year revenue growth (CAGR)
0.45%
10-year revenue growth (CAGR)
5.45%
3-year earnings per share growth (CAGR)
55.64%
10-year earnings per share growth (CAGR)
2.84%
3-year dividend per share growth (CAGR)
23.06%
10-year dividend per share growth (CAGR)
6.01%
What the Analysts think about GBLB
Analyst ratings (Buy, Hold, Sell) for Groupe Bruxelles Lambert stock.
Analyst projections of the future price of Groupe Bruxelles Lambert stock.
Bulls say / Bears say
GBL has sold more than €5bn of non-core and listed holdings since 2024 and is redirecting capital into controlled or co-controlled businesses, where it can play a more active role in value creation. Its three new investments announced in 2026 total about €2.3bn. (GBL)
The direct private healthcare businesses are showing solid momentum: Affidea and Sanoptis helped drive €130m of value uplift in H1 2026, while Affidea’s sales rose 14% and EBITDA increased 9%. Continued organic growth and acquisitions give these holdings a route to expand further. (GBL)
Shareholders received a €5.125 dividend per share, and GBL continued buybacks and cancelled 3.4m treasury shares. At June 2026 the shares still traded at a 20.9% discount to NAV, leaving room for further value recognition if the discount narrows. (GBL)
NAV per share fell 4.4% in the first half of 2026 to €100.77, while total NAV declined 6.8%. That fall shows how quickly market weakness and portfolio changes can erode the underlying value supporting the shares. (GBL)
H1 cash earnings fell to €296m from €320m a year earlier, mainly because GBL received lower dividends from its investments. Weaker recurring cash earnings could make it harder to sustain shareholder distributions without relying on disposals or reserves. (GBL)
The move into larger private investments raises execution and concentration risks: GBL’s planned Recordati offer could require up to €1.3bn, around 10% of its March NAV, and depends on regulatory approval and sufficient shareholder support. A large deal that fails to close or underperforms could tie up capital and weigh on returns. (Moody's Ratings)
Data summarised monthly by Lightyear AI. Last updated on 21 Oct 2026.
GBLB Financial Performance
Revenues and expenses
GBLB Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing GBLB
AllEURUSDGBP
Fund name | Fund size | €GBLB weighting |
|---|---|---|
Invesco EURO STOXX High Dividend Low Volatility£EUHD | €589M | 2.87% |
iShares STOXX Europe 600 Financial Services€EXH2 | €104M | 1.02% |
iShares EURO STOXX Mid€DJMC | €595M | 0.69% |
iShares EURO STOXX Mid Cap£DJMC | €595M | 0.69% |
iShares STOXX Europe Mid 200€EXSD | €610M | 0.34% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.